Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abagovomab

Next Previous
X
Search
Drug Profile

Abagovomab

Alternative Names: ACA 125; Anti-idiotype ovarian cancer vaccine; MAb ACA 125; Monoclonal Anti-idiotype Antibody ACA125

Latest Information Update: 22 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CellControl Biomedical Laboratories
  • Developer Menarini
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 22 Jul 2015 Discontinued - Phase-III for Ovarian cancer in USA and European Union (SC)
  • 23 Jul 2013 Phase-III development appears to be ongoing for Ovarian cancer in US and European Union
  • 17 Nov 2011 Menarini terminates the phase III MIMOSA trial in Ovarian cancer in USA and European Union (NCT00418574)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top